Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

NCT03775707 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Protocol modification

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib
DRUG: PD-1 antibody

Sponsor

Shi Ming